TXG — 10X Genomics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.16bn
- $733.01m
- $610.79m
- 89
- 39
- 66
- 71
Annual cashflow statement for 10X Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -543 | -58.2 | -166 | -255 | -183 |
| Depreciation | |||||
| Non-Cash Items | 361 | 103 | 146 | 187 | 152 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -50.4 | -87.4 | -39.4 | 17.3 | 1.25 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -218 | -21.4 | -33.6 | -15.2 | 6.66 |
| Capital Expenditures | -38.4 | -101 | -132 | -49.5 | -13.4 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | -5.45 | -219 | 183 | -19.2 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -38.4 | -107 | -351 | 133 | -32.6 |
| Financing Cash Flow Items | -5.85 | -5.03 | -5.41 | -5.81 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 469 | 35.3 | 15.8 | 13.7 | 10.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 212 | -92.6 | -369 | 132 | -15.2 |